Moreover, as noted, published studies on CRP and DR have been inconsistent.16 In practice, then, hs-CRP might at best serve as one component of a multifactorial risk model (along with HbA1c, blood pressure, lipid profile, duration, etc).11 From a clinical perspective, hs-CRP is potentially a low-cost and readily available biomarker for addressing the risk of DR in individuals with T2DM, particularly in settings where imaging of the retina is impractical. The gene discussed is CRP; the disease is type 2 diabetes mellitus.